Renata PLC (DSE:RENATA)

Market Cap	47.62B -17.6%
Revenue (ttm)	44.93B +8.6%
Net Income	2.73B -2.9%
EPS	23.80 -3.0%
Shares Out	114.70M
PE Ratio	17.44
Forward PE	15.14
Dividend	5.50 (1.32%)
Ex-Dividend Date	Nov 18, 2025

Volume	30,189
Average Volume	29,750
Open	n/a
Previous Close	415.20
Day's Range	414.20 - 416.50
52-Week Range	372.00 - 548.00
Beta	0.00
RSI	42.14
Earnings Date	Apr 29, 2026

About Renata

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pedia...

• Industry: Pharmaceutical Preparations
• Founded: 1972
• Employees: 8,366
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: RENATA

Financial Performance

In fiscal year 2025, Renata's revenue was 42.89 billion, an increase of 13.74% compared to the previous year's 37.71 billion. Earnings were 2.22 billion, a decrease of -38.58%.